Capricor Therapeutics Inc (NASDAQ:CAPR) shares are trading lower Monday morning after the company reported new data from its exosome-based drug delivery platform. Here’s what investors need to know.
- CAPR is testing critical support. See the full story here.
What To Know: In a presentation at the 2025 American Association for Extracellular Vesicles meeting in Salt Lake City, Capricor unveiled a scalable framework for loading therapeutic oligonucleotides into exosomes.
The work focuses on efficiently packaging small interfering RNAs and phosphorodiamidate morpholino oligomers into engineered exosomes derived from 293F cells using optimized electroporation conditions.
Capricor said both scale-up and scale-out electroporation strategies achieved loading efficiencies comparable to conventional small-volume methods, while enabling production of substantially larger batches of exosome therapeutics.
Management believes the approach could provide a practical pathway to manufacture clinically relevant quantities of loaded exosomes, a key hurdle for advancing the platform into later-stage trials.
Chief Executive Linda Marbán said the findings underscore the strength and versatility of Capricor's exosome technology and its potential to support a broad range of diseases.
Despite Monday's pullback, the update may keep attention on CAPR as investors track progress of its exosome and cell-therapy pipeline.
Benzinga Edge Rankings: Benzinga Edge gives Capricor a Momentum score of 4.84, with weak price trends across short-, medium- and long-term time frames, signaling limited near-term strength.
CAPR Price Action: Capricor Therapeutics shares were down 19.83 % at $4.61 at the time of publication on Monday, according to Benzinga Pro data.
Read Also: A December Rate Cut Coming? Goldman Tells Investors To Buy The Dip
How To Buy CAPR Stock
By now you're likely curious about how to participate in the market for Capricor Therapeutics (NASDAQ:CAPR) – be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of possible trading platforms here. Many will allow you to buy “fractional shares,” which allows you to own portions of stock without buying an entire share.
In the case of Capricor Therapeutics (NASDAQ:CAPR), which is trading at $4.61 as of publishing time, $100 would buy you 21.7 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to “go short” a share of stock by lending you the shares to sell. The process of shorting a stock can be found at this resource. Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading – either way it allows you to profit off of the share price decline.
